Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abuse Potential of Intranasal Esketamine vs IV Ketamine
NCT02682225Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2016
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of esketamine in major depressive disorder (MDD) (6 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change From Baseline in abuse potential based on Visual Analog Scale. Started Mar 2016; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02682225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02682225.